Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gsk Plc ADR (NY: GSK ) 42.63 +0.68 (+1.62%) Official Closing Price Updated: 7:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Gsk Plc ADR < Previous 1 2 3 4 5 6 7 8 9 ... 33 34 Next > Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets August 23, 2024 Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,... Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session August 19, 2024 Via Benzinga Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk August 16, 2024 A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting... Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session August 15, 2024 Via Benzinga Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings July 29, 2024 The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. Via Benzinga Topics Economy Exposures Interest Rates Is GSK a Top-Value Stock Right Now? July 17, 2024 GSK, a multinational pharma company, scans as a bargain. Via The Motley Fool New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules August 13, 2024 Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare disease treatment development by imposing stricter guidelines on medical... Via Benzinga Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields August 12, 2024 Via Benzinga BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows August 07, 2024 Via Investor Brand Network Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% August 06, 2024 From Myriad Genetics, Inc. Via GlobeNewswire Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033 August 06, 2024 EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END Via FinancialNewsMedia Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again. August 05, 2024 Moderna sustained a rare downgrade on Monday following its guidance cut for the year. Via Investor's Business Daily Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer August 02, 2024 Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from... Via Benzinga Exposures COVID-19 Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033 August 06, 2024 From FN Media Group LLC Via GlobeNewswire US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit August 01, 2024 From GSK plc Via Business Wire Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday? July 31, 2024 Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting. Via Benzinga Topics Economy Exposures Interest Rates British Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance July 31, 2024 GSK reported Q2 sales of $9.95 billion, beating estimates of $9.66 billion. Specialty Medicine sales rose 20%, driven by strong HIV, Respiratory/Immunology, and Oncology performance. Core EPS of $1.10... Via Benzinga Topics Earnings Exposures Financial GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix Miss July 31, 2024 The company, however, raised its sales and earnings outlook for the year. Via Investor's Business Daily Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility July 31, 2024 Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro Devices, Inc.‘s (NASDAQ:AMD) Via Benzinga Topics Economy Exposures Interest Rates GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q2 2024 July 31, 2024 GSK stock results show that GSK beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests July 26, 2024 New research suggests that GSK's Shingrix vaccine may reduce dementia risk, potentially revolutionizing treatment for older adults. The study, involving 200,000 people, indicates a significant... Via Benzinga Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial July 23, 2024 ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient... Via Benzinga 3 Stocks Under $10 With the Potential for Massive Gains July 22, 2024 Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries. Via InvestorPlace Top Research Reports For Apple, Lowe's & Shopify July 17, 2024 Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Lowe's Companies, Inc., and Shopify Inc., as well as two micro-cap stocks MIND Technology, Inc., and... Via Talk Markets European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment July 17, 2024 European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. Via Benzinga Exposures COVID-19 3 Top Cancer Treatment Stocks to Buy Now July 17, 2024 These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. Via InvestorPlace Positive News is Driving This Cancer Drug Maker’s Stock Higher July 15, 2024 IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather Via MarketBeat The 3 Most Undervalued Pharma Stocks to Buy in July 2024 July 12, 2024 Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued. Via InvestorPlace Topics Economy Exposures Economy GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season July 11, 2024 From GSK plc Via Business Wire 3 Dirt-Cheap Drug Developers With Blockbuster Potential July 11, 2024 These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. Via InvestorPlace < Previous 1 2 3 4 5 6 7 8 9 ... 33 34 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.